Full-Time

Associate Director

Preclinical Pharmacology

Confirmed live in the last 24 hours

Verve Therapeutics

Verve Therapeutics

201-500 employees

Develops gene editing therapies for cardiovascular disease

Biotechnology
Healthcare

Expert

No H1B Sponsorship

Boston, MA, USA

Considering local candidates only.

Category
Lab & Research
Medical Research
Requirements
  • Bachelor’s degree in biochemistry, molecular biology, biology, pharmacology, pharmaceutical sciences, chemistry, or similar field.
  • At least 9 years of relevant experience in preclinical pharmacology. Ideally within gene editing, gene therapy, or related biotech sectors.
  • In-depth knowledge of pharmacokinetics, pharmacodynamics, in vivo models, and translational research, particularly related to gene editing or genetic therapies.
  • Proven track record of leading preclinical programs from early discovery to IND submission, including biomarker identification.
  • Experience with CRO management and external study collaborations.
  • Possesses excellent verbal and written communication skills, excellent presentation skills, and is detail oriented.
  • Demonstrated ability to collaborate effectively with cross-functional teams to drive program success.
  • Experience with a variety of bioanalytical assay technologies for LNP and nucleic acid drug substances (qPCR, NGS).
  • Possess excellent problem-solving and decision-making skills paired with the ability to provide constructive feedback.
  • Regulatory experience supporting IND submissions or similar filings with the FDA or international regulatory agencies.
Responsibilities
  • Lead a team of scientists to design, oversee, and interpret preclinical pharmacology studies, including efficacy, and PK/PD (pharmacokinetics/pharmacodynamics) for gene editing therapeutics.
  • Develop robust in vivo and ex vivo models to assess therapeutic candidates and inform dose selection and therapeutic windows.
  • Analyze and present preclinical data to internal and external stakeholders, including leadership teams, regulatory agencies, and partners.
  • Work closely with research, bioinformatics, toxicology, and regulatory teams to integrate pharmacology data into program strategies and IND-enabling studies.
  • Manage relationships with CROs (contract research organizations) to ensure high-quality and timely execution of outsourced studies.
  • Provide scientific expertise and contribute to regulatory filings, including IND submissions, in alignment with project timelines.
  • Mentor and manage junior scientists, fostering a collaborative and innovative environment.
  • Keep abreast of the latest advancements in gene editing, pharmacology, and related fields to ensure the company’s approaches remain at the forefront of scientific innovation.
  • Other duties as assigned.

Verve Therapeutics focuses on developing gene editing therapies to treat cardiovascular disease. Their approach involves creating single-course treatments that aim to provide lasting solutions rather than ongoing management. The company targets specific genes, such as PCSK9 and ANGPTL3, which are known to influence blood lipid levels. This targeted gene editing could potentially offer patients a more effective and permanent option for managing their cardiovascular health. Unlike many traditional therapies that require continuous use, Verve's products are designed to be one-time treatments. The goal of Verve Therapeutics is to transform cardiovascular care by providing curative options for patients, ultimately improving their quality of life.

Company Stage

N/A

Total Funding

$353.6M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

6%

1 year growth

8%

2 year growth

34%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant financial backing, including a $63 million Series A2 financing and $60 million from Eli Lilly, positions Verve for robust R&D and clinical trial activities.
  • The potential for a 'one-and-done' treatment for cardiovascular diseases could revolutionize the field and offer a high-impact, life-saving solution.
  • Early-stage success and strategic partnerships could lead to lucrative licensing deals and further investment opportunities.

What critics are saying

  • The clinical-stage nature of Verve's therapies means they are still years away from potential market approval, posing a long-term risk.
  • The recent stock price drop following a public offering indicates market volatility and potential investor uncertainty.

What makes Verve Therapeutics unique

  • Verve Therapeutics focuses on gene-editing therapies specifically for cardiovascular diseases, setting it apart from other CRISPR-based companies that target a broader range of conditions.
  • Their 'one-and-done' gene-editing approach aims to provide a single, curative treatment, which is a significant advantage over traditional, ongoing therapies.
  • Partnerships with major pharmaceutical companies like Eli Lilly enhance their credibility and provide substantial financial and research support.

Help us improve and share your feedback! Did you find this helpful?